Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
RemeGen Co. Ltd. Class H (HK:9995)
HKEX:9995
Holding HK:9995?
Track your performance easily
9995 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$10.20 - HK$49.00
Previous CloseHK$11.48
Volume3.23M
Average Volume (3M)2.31M
Market Cap
HK$11.66B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Oct 24, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares OutstandingN/A
10 Day Avg. Volume2,088,539
30 Day Avg. Volume2,307,010
Standard Deviation0.22
R-Squared0.07
Alpha-0.00559
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)12.13
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.53Price Target Upside61.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
RemeGen Co. Ltd. Class H News
PremiumCompany Announcements
RemeGen Co. Enhances Transparency on Incentive Plans
PremiumCompany Announcements
RemeGen Reports Strong H1 2024 Growth and Clinical Advances
PremiumCompany Announcements
RemeGen Co. Ltd. Schedules Crucial Board Meeting
PremiumCompany Announcements
RemeGen Co. Announces Issuance Plan Adjustments
PremiumCompany Announcements
RemeGen’s Telitacicept Wins NMPA Approval
PremiumCompany Announcements
RemeGen Reports Unusual Share Price Drop
PremiumCompany Announcements
RemeGen Co. Ltd. AGM Concludes with Key Approvals
PremiumCompany Announcements
RemeGen Co. Shareholders Approve Key ProposalsOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
5.58% Mutual Funds
3.43% Other Institutional Investors
90.99% Public Companies and
Individual Investors
9995 FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was HK$10.20 and its highest was HK$49.00 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
Currently, no data Available
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Oct 24, 2024 which is in 34 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Aug 16, 2024. The company reported -HK$1.601 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$1.601.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 189,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of -HK$1.601 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.259%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9995
---
RemeGen Co. Ltd. Class H Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.72%
12-Months-Change
Fundamentals
Return on Equity
-45.84%
Trailing 12-Months
Asset Growth
-1.71%
Trailing 12-Months
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co Ltd is a commercial-ready biopharmaceutical company committed to the discovery, development, and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally. The company's drug candidates include Telitacicept (RC18); Disitamab Vedotin (RC48); RC88; RC98; RC108; RC118; RC138; RC148; RC158; and RC28.
---
9995 Stock 12 Month Forecast
Average Price Target
HK$18.53
▲(61.41% Upside)
Technical Analysis
Viva Biotech Holdings
―
Akeso, Inc.
―
Everest Medicines Ltd.
―
Beijing Airdoc Technology Co. Ltd. Class H
―
Best Analysts Covering 9995
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-54.93%
reiterated a buy rating last month
Copying Jill Wu's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -54.93% per trade.
---